Krystal stock: buy or sell?
February 18th, 2020
Krystal Biotech, Inc., a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases.
Should I buy Krystal stock?Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Krystal stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Krystal Biotech stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't detect any rating for KRYS stock for the last 30 days.
Krystal stock analysis
After climbing to all-time highs several times in past weeks, Krystal dropped -3.33% to $62.21.
After topping to all time highs on Thursday, Krystal Biotech dropped -3.33% to $62.21. On Thursday, KRYS hit a new all time high, pushing higher than on December tops. Check different trading setups that use ATHs as triggers. From a daily perspective, KRYS is in a short term uptrend after plotting its last bottom ($57.31, on February/7) higher than the previous bottom, and its last top ($66.85, on Thursday) also over the previous top. Now trading in between its last bottom and last top KRYS might consolidate in a plain range, waiting to break out over $66.85 or down under $57.31. Since last October when KRYS stock price broke up the SMA200d line, it gained $29.04 (87.55%). Since SMA50d and SMA100d crossed up on December, KRYS price slid a -0.69%.
After boosting a dazzling 8.95% in a week last week, Krystal closed this week at $62.21 and eased a rough -3.33%. Late January KRYS collapsed a frightening -7.19% in just one week.
Not so far away is the last all-time high Krystal Biotech marked last week. Since SMA10d and SMA20w crossed up early December, KRYS price climbed $5.70 per share (10.09%). Since price and SMA20w lines crossed up by mid November 2019, KRYS climbed $19.65 (46.17%).
Krystal stock price history
Krystal stock went public on September 20th, 2017 with a price of $10.501. Since then, KRYS stock grew a 492.50%, with an average of 246.30% per year. If you had invested $1,000 in Krystal stock in 2017, it would worth $4,925.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Krystal stock historical price chart
KRYS stock reached all-time highs on Thursday with a price of $66.85.
Krystal stock price targetPredicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' KRYS stock price predictions in the hope that they will be met as they may be wrong and not met. For the last 30 days we have not detected any price target for Krystal stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareKrystal reported pretty good results for 2018-Q4 on March. Krystal Biotech soared Earnings per Share (EPS) by 16.70%, beating experts of $-0.24. Krystal Biotech posted $-0.28.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to , last anual turnover report draw of to M USD. When comparing vs , , profit margin (that is, the net income divided by revenues) a to .
Quarterly financial resultsReported quarter earnings marked $-3.71 M with a profit margin of . Profit margin remained stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Krystal sales marked a tight move and remained constant a nan%. Looking back to recent quarterly results, Krystal posted 7 negative quarters in a row.
Krystal ownershipWhen you are planning to buy shares of a stock, it's always worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Krystal Biotech, 33.37% of all outstanding shares are owned by its staff.
In case of Krystal stock, 65.14% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for KRYS stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Krystal Biotech:
|Market cap||$1.1 B|
|Total shares||17.3 M|
|Float shares||10.0 M|
|- Institutional holdings (%)||65.1%|
|- Insider holdings (%)||33.4%|
|Shares in short selling||0.0%|
|Tuesday, February 18th, 2020|
|Day range||$61.88 - $64.31|
|Average true range||$3.24|
|50d mov avg||$57.89|
|100d mov avg||$50.92|
|200d mov avg||$45.57|
Krystal performanceTo better understand Krystal performance you must becnhmark its gains with other related stocks in same sector or industry. In the following table, we compare Krystal to :